ArticleTransplantation direct2026
Favorable Adherence and Tolerability of Letermovir Versus Valganciclovir for Cytomegalovirus Prophylaxis in Kidney Transplant Recipients Aged 65 y or Older: Findings From a Randomized, Phase 3 Trial.
Article in Transplantation direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03443869 (A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Older patients undergoing kidney transplantation are at risk of perioperative complications, underscoring the need for optimized care. The number of kidney transplants in older adults has increased in the past decade, with greater reliance on transplants from deceased donors. Methods: The phase 3, randomized, double-blind, active-controlled P002 study evaluated 200 d of letermovir versus valganciclovir prophylaxis in cytomegalovirus-seronegative kidney transplant recipients who received kidneys from cytomegalovirus-seropositive donors. Outcomes among participants aged 65 y or older are reported. Results: Forty-eight and 55 participants aged 65 y or older received letermovir or valganciclovir, respectively. A lower percentage of participants receiving letermovir versus valganciclovir had committee-confirmed cytomegalovirus disease through week 52 posttransplant (9% versus 22%; stratum-adjusted difference, -12% [95% confidence interval [CI], -27% to 2%]), without significant differences in cytomegalovirus disease or viremia between groups. A significantly higher percentage of participants receiving letermovir had ≥90% prophylaxis adherence (96% [95% CI, 86%-100%] versus 49% [95% CI, 35%-63%]). The letermovir group showed numerically lower incidences of drug-related adverse events (25% versus 49%) and study medication discontinuations due to adverse events (10% versus 20%). A significantly lower percentage of participants receiving letermovir had leukopenia or neutropenia events through week 28 posttransplant (31% [95% CI, 19%-46%] versus 62% [95% CI, 48%-75%]). Participants receiving letermovir had numerically lower rates of opportunistic infections (11% versus 25%) and rehospitalizations (51% versus 69%) through week 52 posttransplant. Conclusions: Letermovir showed substantial advantages over valganciclovir in adherence, safety, and tolerability, supporting its use as an important option for cytomegalovirus disease prophylaxis for older patients undergoing kidney transplantation. Clinical trial registration number: ClinicalTrials.gov, NCT03443869.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.